Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 2 of the last 2 fiscal years.
-
Two loss years in a row NBB
Negative result in 2022 and 2023.
-
Tight liquidity NBB
Cash and receivables cover 17 % of short-term debt in 2023; threshold 65 %.
-
Annual account missing NBB
Fiscal year 2024 was expected before 31 July 2025 and has not been filed.
-
Not on Peppol Peppol
Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.
Financials
Financial year 2023
PharmaDEXI from Elsene, company number BE0771461685, closed financial year 2023 with a result of € -14,540 after tax. For that financial year PharmaDEXI recorded a gross margin of € -9,252 and equity of € -40,156. Compared with financial year 2022, the result moved from € -30,616 to € -14,540. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 30, 2024.
€ -40,156
▼ € 14,540 vs 2022
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -14,540
▲ 53 % less loss than in 2022
Profit after tax over the fiscal year.
€ 1,648
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -45,156.
People and assets in 2023
≈ 1
No payroll staff. One director, so that person most likely runs the business.
Debts at end 2023
None
No bank loans on the last day of the fiscal year.
€ 12,422
▼ 8% vs 2022
Supplier invoices still open on the last day of the fiscal year.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | Change 2022 → 2023 | |
|---|---|---|---|
| Gross margin | € -15,918 | € -9,252 | ▲ € 6,666 |
| Profit after taxes | € -30,616 | € -14,540 | ▲ € 16,075 |
| Equity | € -25,616 | € -40,156 | ▼ € 14,540 |
| Total debts | € 57,093 | € 69,612 | ▲ 22% |
| Cash | - | € 1,648 | |
| Retained profit | € -30,616 | € -45,156 | ▼ € 14,540 |
| Bank debt | € 4,510 | € 0 | ▼ 100% |
| Balance sheet total | € 31,477 | € 29,457 | ▼ 6% |
Key figures of PharmaDEXI, fiscal years 2022 to 2023, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2024 has not been filed yet; it was expected before 31 July 2025.
What happened to PharmaDEXI?
What happened at PharmaDEXI in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2023: loss of € 14,540. filed late Source: NBB ↗
- ANDRY RABEMANANTSOA became a director. NBB
- New establishment in Elsene. KBO
- Start of the company according to the CBE. KBO
In short
From € 30,616 loss in 2022 to € 14,540 loss in 2023.
A new publication or filing at PharmaDEXI? We notify you, reason included.
Follow PharmaDEXIDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind PharmaDEXI is ANDRY RABEMANANTSOA.
Directors
According to the 2023 annual accounts
ANDRY RABEMANANTSOA
Director
since 2021
Establishments
Establishment units
Physical locations of this company
Notarisstraat 64
1050 Elsene
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 7 companies are registered at this address.
All companies at this address →Grande Teinturerie Royale
€ 121,581 gross margin · 2025
Mofre
€ 841,610 gross margin · 2025
Monif
€ 238,592 gross margin · 2025
Réseau pluridisciplinaire d'accompagnement et de soutien aux addictions
€ 686,873 gross margin · 2025
Switzerland Cheese Marketing BNL
€ 257,822 gross margin · 2025
+2 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0771.461.685
- VAT number
- BE 0771.461.685
- Registered office
- Notarisstraat 64, 1050 Elsene
- Names & denominations
- PharmaDEXI
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 15 July 2021
- Peppol
- Not registered